Secukinumab is an immunosuppressant that is used to treat psoriasis, ankylosing spondylitis, and psoriatic arthritis. Suppliers of secukinumab market it in the form of 150mg prefilled syringes and 150mg prefilled pens. The developer and manufacturer of secukinumab is Novartis, who first introduced it into the market in 2015 under the trade name Cosentyx. Currently, the drug is approved in and supplied to over 80 countries worldwide. Although the patent for Cosentyx is still valid until 2020 in the U.S., it faces competition from other similar alternatives that treat the same indications. For example manufacturer Ely Lilly markets a pharmaceutical that has a similar mechanism of action under the trade name Taltz. Another example is AbbVie’s flagship product Humira, which is a more costly alternative for the treatment of psoriasis but has slightly outperformed Cosentyx in clinical studies for effectiveness. The retail price of two 150mg prefilled secukinumab syringes is approximately 1,100 EUR. Pharmaceutical specialists are welcome to browse through offers of secukinumab prefilled syringes and prefilled pens from suppliers on our pharmaceutical marketplace, or else seek out further useful medical information about secukinumab online, at the official Cosentyx product website.